MAIA Biotechnology's top three insider shareholders as of September 09, 2026 are Stan Smith (Director, 1.52Mn shares), Ngar Yee Louie (Director, 1.25Mn shares), Vlad Vitoc (Chief Executive Officer, 976.12K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Stan Smith | Director | 0 | 1,519,178 | 1,519,178 | 27.5% | 02 Jun, 2026 |
| 2 | Ngar Yee Louie | Director | 1,248,888 | 0 | 1,248,888 | 22.6% | 22 Dec, 2025 |
| 3 | Vlad Vitoc | Chief Executive Officer | 976,121 | 0 | 976,121 | 17.7% | 02 Jun, 2026 |
| 4 | Ramiro Guerrero | Director | 735,701 | 0 | 735,701 | 13.3% | 01 Sep, 2026 |
| 5 | Cristian Luput | Director | 437,628 | 0 | 437,628 | 7.9% | 28 Nov, 2025 |
| 6 | Laurentiu Vlad | Director | 376,933 | 0 | 376,933 | 6.8% | 02 Aug, 2022 |
| 7 | Steven M Chaouki | Director | 151,873 | 0 | 151,873 | 2.7% | 22 Dec, 2025 |
| 8 | Sergei Gryaznov | Chief Scientific Officer | 46,511 | 0 | 46,511 | 0.8% | 02 Jun, 2026 |
| 9 | Mihail Obrocea | Chief Medical Officer | 27,100 | 0 | 27,100 | 0.5% | 02 Aug, 2022 |
| 10 | Joseph F Mcguire | Chief Financial Officer | 9,400 | 0 | 9,400 | 0.2% | 28 Apr, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 26 Aug, 2026 | Ramiro Guerrero | Director | Acquired P | 8,931 | $1.39 | $12.41K | 610,842 | Direct |
| 27 Aug, 2026 | Ramiro Guerrero | Director | Acquired P | 78,239 | $1.39 | $108.75K | 689,081 | Direct |
| 28 Aug, 2026 | Ramiro Guerrero | Director | Acquired P | 46,620 | $1.35 | $62.94K | 735,701 | Direct |
| 24 Aug, 2026 | Ramiro Guerrero | Director | Acquired P | 1,794 | $1.33 | $2.39K | 601,911 | Direct |
| 20 Aug, 2026 | Ramiro Guerrero | Director | Acquired P | 11,899 | $1.37 | $16.30K | 600,117 | Direct |
| 30 Jun, 2026 | Steven M Chaouki | Director | Acquired A | 26,982 | $0.00 | $0 | 26,982 | Direct |
| 30 Jun, 2026 | Stan Smith | Director | Acquired A | 32,003 | $0.00 | $0 | 32,003 | Indirect |
| 30 Jun, 2026 | Ngar Yee Louie | Director | Acquired A | 32,630 | $0.00 | $0 | 32,630 | Direct |
| 30 Jun, 2026 | Ramiro Guerrero | Director | Acquired A | 26,355 | $0.00 | $0 | 26,355 | Direct |
| 30 Jun, 2026 | Jean-Manasse Theagene | Director | Acquired A | 26,355 | $0.00 | $0 | 26,355 | Direct |
| 30 Jun, 2026 | Cristian Luput | Director | Acquired A | 27,610 | $0.00 | $0 | 27,610 | Direct |
| 01 Jun, 2026 | Vlad Vitoc | Chief Executive Officer | Acquired P | 72,700 | $1.39 | $100.89K | 976,121 | Direct |
| 01 Jun, 2026 | Stan Smith | Director | Acquired P | 75,000 | $1.34 | $100.20K | 1,519,178 | Indirect |
| 01 Jun, 2026 | Sergei Gryaznov | Chief Scientific Officer | Acquired P | 2,000 | $1.35 | $2.69K | 46,511 | Direct |
| 29 May, 2026 | Jeffrey C Himmelreich | Head Of Finance | Acquired A | 60,000 | $0.00 | $0 | 60,000 | Direct |
| 29 May, 2026 | Sergei Gryaznov | Chief Scientific Officer | Acquired A | 400,000 | $0.00 | $0 | 400,000 | Direct |
| 29 May, 2026 | Vlad Vitoc | Chief Executive Officer | Acquired A | 800,000 | $0.00 | $0 | 800,000 | Direct |
| 10 Apr, 2026 | Vlad Vitoc | Chief Executive Officer | Acquired A | 800,000 | $0.00 | $0 | 800,000 | Direct |
| 10 Apr, 2026 | Sergei Gryaznov | Chief Scientific Officer | Acquired A | 400,000 | $0.00 | $0 | 400,000 | Direct |
| 10 Apr, 2026 | Jeffrey C Himmelreich | Head Of Finance | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |